Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Clinical Evaluation of a Novel CRISPR/Cas12a-Based Diagnostic Tool for the Diagnosis of Fungal Endophthalmitis
Author Affiliations & Notes
  • Siddharth Narendran
    Aravind Eye Hospital Coimbatore, Coimbatore, Tamil Nadu, India
    Aravind Medical Research Foundation, Madurai, India
  • Hanith Raj Deivarajan
    Aravind Medical Research Foundation, Madurai, India
  • Lalitha Prajna
    Aravind Medical Research Foundation, Madurai, India
  • N Venkatesh Prajna
    Aravind Medical Research Foundation, Madurai, India
  • Footnotes
    Commercial Relationships   Siddharth Narendran ARAVIND MEDICAL RESEARCH FOUNDATION, Code P (Patent); Hanith Deivarajan None; Lalitha Prajna None; N Venkatesh Prajna None
  • Footnotes
    Support  Velux Stiftung Foundation (Grant number 1465).
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5618. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Siddharth Narendran, Hanith Raj Deivarajan, Lalitha Prajna, N Venkatesh Prajna; Clinical Evaluation of a Novel CRISPR/Cas12a-Based Diagnostic Tool for the Diagnosis of Fungal Endophthalmitis. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5618.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study evaluates the RID-MyC (Rapid Identification of Mycoses using CRISPR), a novel CRISPR-based assay against traditional methods like culture, PCR, and NGS for diagnosing Fungal Endophthalmitis (FE), a major cause of blindness, especially in tropical regions. Current diagnostic approaches often fall short, with culture methods yielding limited results and PCR's effectiveness reduced by intrinsic inhibitors in intraocular fluids. NGS data indicates that many 'culture-negative' FE cases might actually be fungal, highlighting the need for improved diagnostics. The RID-MyC assay's efficacy in accurately identifying FE is thus critically assessed.

Methods : Methods: The study analyzed 119 intraocular specimens from 96 patients suspected of having infective endophthalmitis and 10 control patients using the RID-MyC assay, microscopy, culture, and PCR. Specimens were divided into two aliquots post-collection. One aliquot was used for microbiological identification with Gram stain and culture on blood agar, chocolate agar, thioglycolate broth, brain heart infusion broth, and potato dextrose agar within 30 minutes of collection. The other aliquot was stored at -20°C for DNA extraction. The RID-MyC assay involved recombinase polymerase amplification targeting the 18S rRNA gene, followed by CRISPR/Cas12a reaction. A result was considered positive if it met or exceeded a cut-off threshold based on the negative control samples. Additionally, 36 specimens were selected for targeted 16S and ITS ribosomal RNA sequencing.

Results : None of the 10 control samples tested positive for fungal endophthalmitis (FE) using culture, PCR, or RID-MyC. Among 109 specimens from suspected patients, detection rates were 9% for culture, 13.8% for PCR, and 23.8% for RID-MyC. Concordance rates were 42% between RID-MyC and PCR, and 87% with NGS. Median time for a positive RID-MyC result was 61.5 minutes, varying by specimen type but not significantly. Endogenous endophthalmitis cases took longer to diagnose (73.75 minutes) compared to trauma-induced (59.7 minutes) and postoperative cases (52.25 minutes), with a significant association found in multivariate analysis for longer diagnosis time in endogenous cases.

Conclusions : The rapidity, superior sensitivity, specificity and cost-effectiveness of the CRISPR-based RID-MyC assay make it a valuable tool for diagnosing fungal endophthalmitis.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×